Nuveen Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $7.23M | Sell |
1,069,950
-53,835
| -5% | -$364K | ﹤0.01% | 1786 |
|
|
2024
Q3 | $7.41M | Buy |
1,123,785
+373,632
| +50% | +$2.46M | ﹤0.01% | 1790 |
|
|
2024
Q2 | $5.63M | Sell |
750,153
-46,749
| -6% | -$351K | ﹤0.01% | 1891 |
|
|
2024
Q1 | $7.95M | Buy |
796,902
+239,999
| +43% | +$2.39M | ﹤0.01% | 1738 |
|
|
2023
Q4 | $5.49M | Sell |
556,903
-430,436
| -44% | -$4.24M | ﹤0.01% | 1926 |
|
|
2023
Q3 | $7.55M | Sell |
987,339
-138,306
| -12% | -$1.06M | ﹤0.01% | 1639 |
|
|
2023
Q2 | $8.41M | Buy |
1,125,645
+100,060
| +10% | +$747K | ﹤0.01% | 1619 |
|
|
2023
Q1 | $6.84M | Sell |
1,025,585
-121,844
| -11% | -$813K | ﹤0.01% | 1712 |
|
|
2022
Q4 | $8.85M | Buy |
1,147,429
+300,292
| +35% | +$2.32M | ﹤0.01% | 1577 |
|
|
2022
Q3 | $9.01M | Buy |
847,137
+278,555
| +49% | +$2.96M | ﹤0.01% | 1542 |
|
|
2022
Q2 | $4.63M | Buy |
568,582
+129,122
| +29% | +$1.05M | ﹤0.01% | 1992 |
|
|
2022
Q1 | $2.91M | Buy |
439,460
+69,254
| +19% | +$458K | ﹤0.01% | 2338 |
|
|
2021
Q4 | $6.68M | Buy |
370,206
+278,323
| +303% | +$5.02M | ﹤0.01% | 1939 |
|
|
2021
Q3 | $2.46M | Buy |
91,883
+13,153
| +17% | +$353K | ﹤0.01% | 2580 |
|
|
2021
Q2 | $2.87M | Buy |
+78,730
| New | +$2.87M | ﹤0.01% | 2537 |
|